Literature DB >> 22680838

The interaction of electrodermal activity and expressed emotion in predicting symptoms in recent-onset schizophrenia.

Kenneth L Subotnik1, Anne M Schell, Mark S Chilingar, Michael E Dawson, Joseph Ventura, Kimberle A Kelly, Gerhard S Hellemann, Keith H Nuechterlein.   

Abstract

In the present study, expressed emotion (EE) was assessed among immediate family members of 94 recent-onset schizophrenia patients at initial study entry point, and patients' electrodermal activity (EDA) was measured without the presence of family members at a baseline outpatient stabilization assessment. Psychiatric symptoms were also rated, both at the baseline outpatient test and at 1-year follow-up. Electrodermal activity × expressed emotion interactions were observed at both test points. In each case, the highest levels of negative symptoms were observed among those who exhibited greater EDA and lived in a high-EE environment. These results support the view that the combination of high family EE and sympathetic nervous system arousal confer especially high risk for poor negative symptom outcomes.
Copyright © 2012 Society for Psychophysiological Research.

Entities:  

Mesh:

Year:  2012        PMID: 22680838      PMCID: PMC3399973          DOI: 10.1111/j.1469-8986.2012.01383.x

Source DB:  PubMed          Journal:  Psychophysiology        ISSN: 0048-5772            Impact factor:   4.016


  24 in total

1.  Paths to relapse: possible transactional processes connecting patient illness onset, expressed emotion, and psychotic relapse.

Authors:  K H Nuechterlein; K S Snyder; J Mintz
Journal:  Br J Psychiatry Suppl       Date:  1992-10

2.  Level of arousal and the subclassification of schizophrenia.

Authors:  P H VENABLES; J K WING
Journal:  Arch Gen Psychiatry       Date:  1962-08

3.  Cognitive and psychophysiological correlates of positive, negative, and disorganized symptoms in the schizophrenia spectrum.

Authors:  J S Brekke; A Raine; C Thomson
Journal:  Psychiatry Res       Date:  1995-08-28       Impact factor: 3.222

Review 4.  Schizophrenia: a neural diathesis-stress model.

Authors:  E F Walker; D Diforio
Journal:  Psychol Rev       Date:  1997-10       Impact factor: 8.934

5.  Prediction of the deficit syndrome from initial deficit symptoms in the early course of schizophrenia.

Authors:  K L Subotnik; K H Nuechterlein; J Ventura; M F Green; S S Hwang
Journal:  Psychiatry Res       Date:  1998-07-27       Impact factor: 3.222

6.  Patient psychopathology and expressed emotion in schizophrenia.

Authors:  S M Glynn; E T Randolph; S Eth; G G Paz; G B Leong; A L Shaner; A Strachan
Journal:  Br J Psychiatry       Date:  1990-12       Impact factor: 9.319

7.  Concurrent and predictive electrodermal correlates of symptomatology in recent-onset schizophrenic patients.

Authors:  M E Dawson; K H Nuechterlein; A M Schell; J Mintz
Journal:  J Abnorm Psychol       Date:  1992-02

8.  Autonomic abnormalities in schizophrenia. State or trait indicators?

Authors:  M E Dawson; K H Nuechterlein; A M Schell; M Gitlin; J Ventura
Journal:  Arch Gen Psychiatry       Date:  1994-10

9.  Electrodermal activity and clinical status in chronic schizophrenia.

Authors:  J Katsanis; W G Iacono
Journal:  J Abnorm Psychol       Date:  1994-11

10.  Developmental Processes in Schizophrenic Disorders: longitudinal studies of vulnerability and stress.

Authors:  K H Nuechterlein; M E Dawson; M Gitlin; J Ventura; M J Goldstein; K S Snyder; C M Yee; J Mintz
Journal:  Schizophr Bull       Date:  1992       Impact factor: 9.306

View more
  2 in total

1.  Parental criticism and behavior problems in children with autism spectrum disorder.

Authors:  Jason K Baker; Rachel M Fenning; Mariann A Howland; David Huynh
Journal:  Autism       Date:  2018-11-03

2.  Computer-aided learning for managing stress: A feasibility trial with clinical high risk adolescents and young adults.

Authors:  Kristen A Woodberry; Cole Chokran; Kelsey A Johnson; Keith H Nuechterlein; David J Miklowitz; Stephen V Faraone; Larry J Seidman
Journal:  Early Interv Psychiatry       Date:  2020-04-01       Impact factor: 2.721

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.